0.00
0.00%
Close of 2 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Nexien Biopharma
Its shares trade under the ticker NXEN. It has been listed since 11 July 2001.
Nexien BioPharma, Inc. engages in the development and commercialization of Food and Drug Administration-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. The company is headquartered in Glendale, Colorado. The company went IPO on 2001-07-11. The firm is engaged in the business of developing drugs containing cannabinoids or terpenes, for the treatment of various diseases, disorders and medical conditions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 11 Jul 2001
- Employees
- 682
- Website
- nexienbiopharma.com ↗
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Nexien Biopharma Inc has a strong portfolio of innovative pharmaceutical products with proven efficacy, giving it a competitive edge in the market.
- The company has a highly skilled and experienced research and development team, enabling them to conduct cutting-edge research and develop new drugs efficiently.
- Nexien Biopharma Inc has established strategic partnerships with leading academic institutions and healthcare providers, allowing for collaborative research and market expansion opportunities.
Weaknesses
- One of the weaknesses of Nexien Biopharma Inc is its heavy reliance on a limited number of key products, which makes it vulnerable to market fluctuations and competition.
- The company's manufacturing processes and supply chain may not be optimized for large-scale production, leading to potential bottlenecks and delays.
- Nexien Biopharma Inc may lack brand recognition and market presence compared to established pharmaceutical giants, making it challenging to penetrate new markets and gain market share.
Opportunities
- The growing demand for innovative pharmaceutical solutions presents a significant opportunity for Nexien Biopharma Inc to expand its product portfolio and capture new market segments.
- Emerging markets, particularly in developing countries, offer untapped potential for Nexien Biopharma Inc to establish a strong presence and cater to the healthcare needs of the population.
- Advancements in technology and personalized medicine open doors for Nexien Biopharma Inc to leverage precision therapies and develop customized treatment options for patients, enhancing their competitive advantage.
Threats
- Intense competition within the pharmaceutical industry poses a threat to Nexien Biopharma Inc, as larger competitors may have greater resources and marketing capabilities.
- Stringent regulatory requirements and potential changes in healthcare policies could increase compliance costs for Nexien Biopharma Inc and create market uncertainties.
- Intellectual property infringement and the emergence of generic drug alternatives may diminish the exclusivity and profitability of Nexien Biopharma Inc's patented products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.